Gilead Sciences (GILD) Gains from Investment Securities (2009 - 2026)

Gilead Sciences has reported Gains from Investment Securities for 18 years, with the latest figure at $17.0 million in Q1 2026.

• For the quarter ending Q1 2026, Gains from Investment Securities rose 103.99% year-over-year to $17.0 million; the trailing twelve-month figure through Mar 2026 stood at $441.0 million (up 192.07% YoY), and the FY2025 full-year result was -$2.0 million, up 96.55% from the prior year.
• Gains from Investment Securities for Q1 2026 stood at $17.0 million, up from -$11.0 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $661.0 million in Q3 2024, with the low at -$640.0 million in Q3 2022.
• Historically, Gains from Investment Securities has averaged -$16.1 million across 5 years, with a median of -$19.5 million in 2025.
• Annual changes were most pronounced in 2023 — Gains from Investment Securities soared 824.59% — and 2025, when it slumped 8420.0%.
• Gilead Sciences' Gains from Investment Securities stood at -$61.0 million in 2022, then soared by 824.59% to $442.0 million in 2023, then slumped by 215.61% to -$511.0 million in 2024, then surged by 97.85% to -$11.0 million in 2025, then surged by 254.55% to $17.0 million in 2026.
• The last three Gains from Investment Securities figures came in at $17.0 million (Q1 2026), -$11.0 million (Q4 2025), and -$28.0 million (Q3 2025), per Business Quant data.